AIM’s Latest Newsletter: The Research Edition, July 2023

Published:  
08/01/2023
Categories:  
Blog - Melanoma360
 | 
Melanoma Research
Image

This month’s newsletter focuses on the latest news and scientific breakthroughs in melanoma research.

This edition features:

  • Letter from AIM’s President, Sam Guild
  • Notes From the Lab: Novel Targets for Immune Checkpoint Inhibitors
    By Paul Bunk, Ph.D. candidate, Cold Springs Harbor Laboratory
  • In Plain English: Neoadjuvant Therapy for Melanoma, and How We Got Here
    By Kim Margolin, M.D., FACP, FASCO
  • Clinical Trials Catch Up: An Interview with Joshua M.V. Mammen, M.D., Ph.D., F.A.C.S.
    By Alicia Rowell, Vice President, AIM at Melanoma

Recent Posts

Featured image for “Coping with Cancer: DBT Skills for Emotional Resilience”
Jun. 10, 2025

Coping with Cancer: DBT Skills for Emotional Resilience

Featured image for “May in Review: A Marathon Month of Melanoma Awareness, Education, and Community”
Jun. 06, 2025

May in Review: A Marathon Month of Melanoma Awareness, Education, and Community

Featured image for “AIM at Melanoma’s 4th Annual Evening in Memory of Valerie Guild”
Jun. 06, 2025

AIM at Melanoma’s 4th Annual Evening in Memory of Valerie Guild

Featured image for “Nivolumab at Micro Doses Works Better than Chemotherapy Against Relapsed Cancer”
Jun. 05, 2025

Nivolumab at Micro Doses Works Better than Chemotherapy Against Relapsed Cancer

Featured image for “The Time of Day Pembrolizumab is Administered May Link to Patient Survival”
Jun. 05, 2025

The Time of Day Pembrolizumab is Administered May Link to Patient Survival

Filter by Tag